<span item_type="fundamental" item_id="54701355dcb454f6964dd4b3938cddf2" counter_id="ST/US/CAI" env="prod"></span><span item_type="announcement" item_id="604070636809946369" env="prod"></span><p>Revenue: As of FY2025 Q4, the actual value is USD 281 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Fourth Quarter 2025</strong>: Total revenue was approximately $281 million, a 116% increase from the same period in 2024. This included approximately $270 million from Molecular Profiling services (with $81 million from prior period true-ups) and $11 million from Pharma research and developmental services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai_ex99-1.htm"></span></li><li><strong>Full Year 2025</strong>: Total revenue was approximately $800 million, a 94% increase from 2024. This comprised approximately $755 million from Molecular Profiling services (with $33 million from prior year true-ups) and $45 million from Pharma research and developmental services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai_ex99-1.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Clinical Therapy Selection Cases</strong>: In the fourth quarter, approximately 52,700 cases were completed, a 20% increase, including 44,150 MI Profile cases and 8,550 Caris Assure cases. For the full year, approximately 199,300 cases were completed, a 22% increase, including 170,300 MI Profile cases and 29,000 Caris Assure cases.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai_ex99-1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Cash and Equivalents</strong>: Preliminary unaudited cash, cash equivalents, restricted cash, and marketable securities were approximately $802 million as of December 31, 2025, a net increase of approximately $43 million from September 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai_ex99-1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Caris Life Sciences plans to report its complete fourth quarter and full year 2025 financial results during its earnings call in late February 2026. The company is focused on expanding clinical adoption, advancing a differentiated pipeline, and building a foundation for a new standard in precision medicine.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2019410/000201941026000005/cai_ex99-1.htm"></span></li></ul>

Caris Life Sciences | 8-K: FY2025 Q4 Revenue: USD 281 M